JPH10501135A - 免疫抑制剤標的蛋白質 - Google Patents
免疫抑制剤標的蛋白質Info
- Publication number
- JPH10501135A JPH10501135A JP8501081A JP50108196A JPH10501135A JP H10501135 A JPH10501135 A JP H10501135A JP 8501081 A JP8501081 A JP 8501081A JP 50108196 A JP50108196 A JP 50108196A JP H10501135 A JPH10501135 A JP H10501135A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- polypeptide
- rapamycin
- rap
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 469
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 266
- 229960003444 immunosuppressant agent Drugs 0.000 title description 4
- 239000003018 immunosuppressive agent Substances 0.000 title description 4
- 230000001861 immunosuppressant effect Effects 0.000 title description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 221
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims abstract description 134
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims abstract description 130
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 212
- 229960002930 sirolimus Drugs 0.000 claims description 206
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 200
- 210000004027 cell Anatomy 0.000 claims description 185
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 175
- 229920001184 polypeptide Polymers 0.000 claims description 161
- 101710126837 Alpha-2-macroglobulin receptor-associated protein Proteins 0.000 claims description 150
- 101710142052 Serine/threonine-protein kinase mTOR Proteins 0.000 claims description 143
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims description 135
- 150000007523 nucleic acids Chemical class 0.000 claims description 122
- 230000027455 binding Effects 0.000 claims description 119
- 102000039446 nucleic acids Human genes 0.000 claims description 106
- 108020004707 nucleic acids Proteins 0.000 claims description 106
- 238000000034 method Methods 0.000 claims description 99
- 230000014509 gene expression Effects 0.000 claims description 93
- 125000003729 nucleotide group Chemical group 0.000 claims description 84
- 239000002773 nucleotide Substances 0.000 claims description 82
- 239000012634 fragment Substances 0.000 claims description 67
- 238000003556 assay Methods 0.000 claims description 64
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 58
- 230000003993 interaction Effects 0.000 claims description 56
- 238000012360 testing method Methods 0.000 claims description 47
- 102000037865 fusion proteins Human genes 0.000 claims description 46
- 108020001507 fusion proteins Proteins 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 45
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 44
- 239000000523 sample Substances 0.000 claims description 43
- 238000013518 transcription Methods 0.000 claims description 38
- 230000035897 transcription Effects 0.000 claims description 38
- 230000001419 dependent effect Effects 0.000 claims description 37
- 230000001105 regulatory effect Effects 0.000 claims description 30
- 230000035772 mutation Effects 0.000 claims description 29
- 238000003752 polymerase chain reaction Methods 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 26
- 102000004190 Enzymes Human genes 0.000 claims description 26
- 108090000790 Enzymes Proteins 0.000 claims description 26
- 108091034117 Oligonucleotide Proteins 0.000 claims description 26
- 230000004927 fusion Effects 0.000 claims description 25
- 108091026890 Coding region Proteins 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 238000012216 screening Methods 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 23
- 230000006870 function Effects 0.000 claims description 23
- 239000005557 antagonist Substances 0.000 claims description 20
- 230000000692 anti-sense effect Effects 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 230000004568 DNA-binding Effects 0.000 claims description 17
- 239000000556 agonist Substances 0.000 claims description 16
- 230000003902 lesion Effects 0.000 claims description 15
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 14
- 230000002068 genetic effect Effects 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- 108091006106 transcriptional activators Proteins 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000009396 hybridization Methods 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims description 8
- 102100039556 Galectin-4 Human genes 0.000 claims description 7
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 7
- 230000010261 cell growth Effects 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 6
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims description 5
- -1 LexA Proteins 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 230000009977 dual effect Effects 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 101150022075 ADR1 gene Proteins 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 102000017343 Phosphatidylinositol kinases Human genes 0.000 claims description 2
- 108050005377 Phosphatidylinositol kinases Proteins 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 230000008711 chromosomal rearrangement Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims 4
- 230000025053 regulation of cell proliferation Effects 0.000 claims 2
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 claims 1
- 230000002301 combined effect Effects 0.000 claims 1
- 230000004853 protein function Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 238000010396 two-hybrid screening Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 233
- 239000003814 drug Substances 0.000 description 52
- 229940079593 drug Drugs 0.000 description 51
- 239000013612 plasmid Substances 0.000 description 51
- 239000013598 vector Substances 0.000 description 48
- 108020004414 DNA Proteins 0.000 description 44
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 42
- 210000001519 tissue Anatomy 0.000 description 39
- 241000282414 Homo sapiens Species 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 29
- 108020004635 Complementary DNA Proteins 0.000 description 28
- 108700019146 Transgenes Proteins 0.000 description 28
- 238000010804 cDNA synthesis Methods 0.000 description 28
- 239000002299 complementary DNA Substances 0.000 description 28
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 26
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 26
- 102000014914 Carrier Proteins Human genes 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 24
- 108091008324 binding proteins Proteins 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 23
- 230000001404 mediated effect Effects 0.000 description 22
- 241000700605 Viruses Species 0.000 description 21
- 230000004071 biological effect Effects 0.000 description 18
- 241000588724 Escherichia coli Species 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 241001430294 unidentified retrovirus Species 0.000 description 16
- 241000222122 Candida albicans Species 0.000 description 15
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 15
- 238000010367 cloning Methods 0.000 description 15
- 238000002703 mutagenesis Methods 0.000 description 15
- 231100000350 mutagenesis Toxicity 0.000 description 15
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 15
- 230000009261 transgenic effect Effects 0.000 description 15
- 108010091086 Recombinases Proteins 0.000 description 14
- 101150106148 TOR1 gene Proteins 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 14
- 229920002477 rna polymer Polymers 0.000 description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 13
- 102000018120 Recombinases Human genes 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 230000006798 recombination Effects 0.000 description 13
- 210000004885 white matter Anatomy 0.000 description 13
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 12
- 230000009918 complex formation Effects 0.000 description 12
- 238000010276 construction Methods 0.000 description 12
- 238000001415 gene therapy Methods 0.000 description 12
- 230000002163 immunogen Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000005215 recombination Methods 0.000 description 12
- 101150049389 tor2 gene Proteins 0.000 description 12
- 102000044980 human MTOR Human genes 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 241000701161 unidentified adenovirus Species 0.000 description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 229960001153 serine Drugs 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 101100502845 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FPR1 gene Proteins 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 230000001177 retroviral effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000002103 transcriptional effect Effects 0.000 description 9
- 239000013603 viral vector Substances 0.000 description 9
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
- 108010036949 Cyclosporine Proteins 0.000 description 8
- 102000005720 Glutathione transferase Human genes 0.000 description 8
- 108010070675 Glutathione transferase Proteins 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 108090000848 Ubiquitin Proteins 0.000 description 8
- 102000044159 Ubiquitin Human genes 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 229960001265 ciclosporin Drugs 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229960003136 leucine Drugs 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 210000005253 yeast cell Anatomy 0.000 description 8
- 229930105110 Cyclosporin A Natural products 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
- 238000001476 gene delivery Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 108010051219 Cre recombinase Proteins 0.000 description 6
- 206010017533 Fungal infection Diseases 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 101100370098 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TOR2 gene Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 229960004452 methionine Drugs 0.000 description 6
- 238000000520 microinjection Methods 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000007423 screening assay Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 102100030891 Actin-associated protein FAM107A Human genes 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 101001063917 Homo sapiens Actin-associated protein FAM107A Proteins 0.000 description 5
- 101100446641 Homo sapiens FKBP1A gene Proteins 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 235000019688 fish Nutrition 0.000 description 5
- 102000055209 human FKBP1A Human genes 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000022983 regulation of cell cycle Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 108091007914 CDKs Proteins 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 4
- 102000001493 Cyclophilins Human genes 0.000 description 4
- 108010068682 Cyclophilins Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108091011114 FK506 binding proteins Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 108010085220 Multiprotein Complexes Proteins 0.000 description 4
- 102000007474 Multiprotein Complexes Human genes 0.000 description 4
- 101000623852 Mus musculus Serine/threonine-protein kinase mTOR Proteins 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 239000003429 antifungal agent Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 125000001151 peptidyl group Chemical group 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229960002898 threonine Drugs 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical group C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 3
- 101150009006 HIS3 gene Proteins 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000144128 Lichtheimia corymbifera Species 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 210000004671 cell-free system Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000004581 coalescence Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 229940041033 macrolides Drugs 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000006916 protein interaction Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100034682 26S proteasome regulatory subunit 7 Human genes 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 201000002909 Aspergillosis Diseases 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 208000036641 Aspergillus infections Diseases 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 241001598984 Bromius obscurus Species 0.000 description 2
- 241000222173 Candida parapsilosis Species 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 101001090865 Homo sapiens 26S proteasome regulatory subunit 7 Proteins 0.000 description 2
- 101000827313 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101150084044 P gene Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102100026408 Peptidyl-prolyl cis-trans isomerase FKBP2 Human genes 0.000 description 2
- 102100023846 Peptidyl-prolyl cis-trans isomerase FKBP3 Human genes 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 102100037935 Polyubiquitin-C Human genes 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 240000005384 Rhizopus oryzae Species 0.000 description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 206010061418 Zygomycosis Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940055022 candida parapsilosis Drugs 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007878 drug screening assay Methods 0.000 description 2
- 230000008846 dynamic interplay Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000012203 high throughput assay Methods 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 201000007524 mucormycosis Diseases 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 101150096273 ADE2 gene Proteins 0.000 description 1
- 101150019478 APT1 gene Proteins 0.000 description 1
- 101710197241 Accessory gland-specific peptide 70A Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001514645 Agonis Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 description 1
- 108050009514 Antigen peptide transporter 1 Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 206010061765 Chromosomal mutation Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000222175 Diutina rugosa Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101100385233 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) creD gene Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101710104441 FK506-binding protein 1 Proteins 0.000 description 1
- 101710132880 FK506-binding protein 1A Proteins 0.000 description 1
- 101710132879 FK506-binding protein 1B Proteins 0.000 description 1
- 108010069271 FKBP-13 Proteins 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 108010028690 Fish Proteins Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000004707 G1/S transition Effects 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000792933 Homo sapiens AT-rich interactive domain-containing protein 4A Proteins 0.000 description 1
- 101000836956 Homo sapiens Alpha-2-macroglobulin receptor-associated protein Proteins 0.000 description 1
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101001060744 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 description 1
- 101000756373 Homo sapiens Retinol-binding protein 1 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 101000836955 Mus musculus Alpha-2-macroglobulin receptor-associated protein Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000036830 Normal foetus Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 description 1
- 102100022369 Peripheral-type benzodiazepine receptor-associated protein 1 Human genes 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000004364 Rhinosporidiosis Diseases 0.000 description 1
- 241000235525 Rhizomucor pusillus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000047339 Salicornia brachystachya Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101150094640 Siae gene Proteins 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 241000186986 Streptomyces anulatus Species 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 241000283907 Tragelaphus oryx Species 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 150000001538 azepines Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000009743 cell cycle entry Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002742 combinatorial mutagenesis Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000023753 dehiscence Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 125000001965 gamma-lactamyl group Chemical group 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- IUAYMJGZBVDSGL-XNNAEKOYSA-N gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 description 1
- 229950009774 gramicidin s Drugs 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000003165 hybrid screening Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108090000446 ribonuclease T(2) Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108010067247 tacrolimus binding protein 4 Proteins 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 101150093706 tor gene Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- KCVMHSHUKPKSDU-KLYOSARXSA-N vir-163 Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CSSC1 KCVMHSHUKPKSDU-KLYOSARXSA-N 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Computational Biology (AREA)
- Physiology (AREA)
- Botany (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 配列番号2もしくは12に少なくとも70%相同なアミノ酸配列を有す るRAPT1ポリペプチドもしくはその断片の実質的に純粋な調製物。 2. 前記ポリペプチドがFKBP/ラパマイシン複合体に結合する、請求の 範囲1のポリペプチド。 3. 配列番号2もしくは18のアミノ酸配列に少なくとも95%相同なアミ ノ酸配列を有する、請求の範囲1のポリペプチド。 4. 前記ポリペプチドが細胞増殖のラパマイシン調節のアゴニスト、もしく は細胞増殖のラパマイシン調節のアンタゴニストのいずれかの役割の内の一つと して機能する、請求の範囲1のポリペプチド。 5. 前記ポリペプチドがATCC受託番号75787のpIC524クロー ンから産生される組換え蛋白質である、請求の範囲1のポリペプチド。 6. ポリペプチドが哺乳類起源のものである、請求の範囲1のポリペプチド 。 7. 請求の範囲1のポリペプチドのエピトープと特異的に反応する抗体調製 物。 8. 配列番号のVal26−Tyr160および配列番号12のVal20 12−Tyr2144の内の一つもしくは両方に少なくとも70%相同なアミノ 酸配列を有するラパマイシン−結合性ドメインを含む、単離されたポリペプチド もしくは組換えポリペプチド。 9. FKBP/ラパマイシン複合体と特異的に結合し、その結合性 がラパマイシン−依存的である可溶性ポリペプチド。 10. そのポリペプチドが前記FKBP/ラパマイシン複合体に結合するRA PT1−様ポリペプチドの可溶性部分を含む、請求の範囲9のポリペプチド。 11. 前記RAPT1−様ポリペプチド部分が、配列番号2のVal26−T yr160、配列番号12のVal2012−Tyr2144、配列番号14の Val41−Tyr173、配列番号16のVal1−Tyr133、および配 列番号18のVal1−Agr133からなる群より選択されるアミノ酸配列に より表されるラパマイシン−結合性ドメインと同一もしくは相同なアミノ酸を有 する、請求の範囲9のポリペプチド。 12. そのポリペプチドが、前記FKBP/ラパマイシン複合体に結合するた めの第一ポリペプチド部分、および前記第一ポリペプチド部分に無関係なアミノ 酸配列を有する第二ポリペプチド部分を含む融合ポリペプチドである、請求の範 囲1のポリペプチド。 13. 前記第二ポリペプチド部分により前記融合蛋白質の存在を検出するため の検出用ラベルが提供される、請求の範囲12のポリペプチド。 14. 前記第二ポリペプチド部分により不溶性マトリックス上に前記融合蛋白 質を固定化するためのマトリックス−結合性ドメインが提供される、請求の範囲 12のポリペプチド。 15. 前記融合ポリペプチドがラパマイシン−依存的二重ハイブリッドアッセ イにおいて機能を示す、請求の範囲12のポリペプチド。 16. RAPT1−様ポリペプチドのラパマイシン−結合性ドメインを含み、 ラパマイシン−依存的様式でFKBP/ラパマイシン複合体と 特異的に結合する可溶性蛋白質。 17. 前記ラパマイシン−結合性ドメインが、配列番号2のVal26−Ty r160、配列番号12のVal2012−Tyr2144、配列番号14のV al41−Try173、配列番号16のVal1−Tyr133、および配列 番号18のVal1−Arg133からなる群より選択されるアミノ酸配列によ り表されるラパマイシン−結合性ドメインと同一もしくは相同なアミノ酸配列を 有する、請求の範囲16の蛋白質。 18. このペプチドが一般式Z1−Z2−Z3[式中、 Z1は、配列番号12の残基1272〜1444内に含まれるラパマイシン−結 合性ドメインを表し、 Z2は、非存在であるか、あるいは前記ラパマイシン−結合性ドメインの直ぐN −末端側にある配列番号12の1から約500アミノ酸残基までのポリペプチド を表し、そして Z3は、非存在であるか、あるいは前記ラパマイシン−結合性ドメインの直ぐC −末端側にある配列番号2の1から約365アミノ酸残基までのポリペプチドを 表し、 前記ポリペプチドがラパマイシン−依存的様式でFKBP/ラパマイシン複合体 と特異的に結合する] により表される、RAPT1蛋白質の可溶性ポリペプチド部分。 19. 一般式A−B−C[式中、 Bは、主に配列番号12のアミノ酸残基2014〜2144からなるラパマイシ ン−結合性ドメイン、もしくはそれに相同なRAPT1−様蛋白質の対応性ラパ マイシン−結合性ドメインを表し、そして XおよびZは個別に非存在であるか、あるいはRAPT1−様蛋白質と無関係な アミノ酸配列を有するポリペプチドを表す] により表されるキメラポリペプチド。 20. RAPT1蛋白質もしくは配列番号2もしくは12の内の一つもしくは 両方に少なくとも70%相同なアミノ酸配列を有するその断片をコードするヌク レオチド配列を有する実質的に純粋な核酸。 21. 前記RAPT1蛋白質がFKBP/ラパマイシン複合体に結合する、請 求の範囲20の核酸。 22. 前記RAPT1蛋白質が、細胞増殖のラパマイシン調節のアゴニストも しくは細胞増殖のラパマイシン調節のアンタゴニストの役割のいずれかの内の一 つとして機能する、請求の範囲20の核酸。 23. 前記RAPT1蛋白質がホスファチジルイノシトールキナーゼ活性を有 する、請求の範囲20の核酸。 24. ATCC受託番号75787のpIC524クローンからのRAPT1 コーディング配列を含む、請求の範囲20の核酸。 25. 緊縮条件下で、配列番号1もしくは11の内の少なくとも12の連続的 ヌクレオチドに相当する核酸プローブにハイブリダイズする、請求の範囲20の 核酸。 26. 前記ヌクレオチド配列を発現ベクターとしての使用に適切なものにする ように前記ヌクレオチド配列に操作的に連結される転写調節配列を更に含む、請 求の範囲20の核酸。 27. 原核生物細胞および真核生物細胞の内の少なくとも一つの中で複製する ことが可能であり、請求の範囲26の核酸を含む、発現ベクター。 28. 請求の範囲27の発現ベクターでトランスフェクトさせ、かつ前記ポリ ペプチドを発現する宿主細胞。 29. 前記RAPT1蛋白質を発現させるために細胞培養培地中で請求項28 の細胞を培養し、そして前記細胞培養物から前記RAPT1蛋白質を単離するこ とを含む、組換えRAPT1蛋白質の産生方法。 30. FKBP/ラパマイシン複合体と特異的に結合し、その結合がラパマイ シン−依存的である、可溶性ポリペプチドをコードする核酸。 31. 前記可溶性ポリペプチドが、配列番号2のVal26−Tyr160、 配列番号12のVal2012−Tyr2144、配列番号14のVal41− Tyr173、配列番号16のVal1−Tyr133、および配列番号18の Val1−Arg133からなる群より選択されるアミノ酸配列により表される ラパマイシン−結合性ドメインと同一もしくは相同なアミノ酸配列を含む、請求 の範囲30の核酸。 32. その核酸が、前記FKBP/ラパマイシン複合体に結合するための第一 ポリペプチド部分、および前記第一ポリペプチド部分に無関係なアミノ酸配列を 有する第二ポリペプチド部分を含む融合ポリペプチドをコードする、請求の範囲 30の核酸。 33. 前記第二ポリペプチドにより前記融合蛋白質の存在を検出するための検 出性ラベルが提供される、請求の範囲32の核酸。 34. 前記第二ポリペプチド部分により不溶性マトリックス上に前記融合蛋白 質を固定化するためのマトリックス−結合性ドメインが提供される、請求の範囲 32の核酸。 35. 前記融合ポリペプチドがラパマイシン−依存的二重ハイブリッドアッセ イにおいて機能を示す、請求の範囲32の核酸。 36. RAPT1ポリペプチドのポリペプチド部分をコードし、そのポリペプ チドがラパマイシン−依存的様式でFKBP/ラパマイシン複合体と特異的に結 合し、そして一般式Z1−Z2−Z3[式中、 Z1は、配列番号12の残基1272〜1444内に含まれるラパマイシン−結 合性ドメインを表し、 Z2は、非存在であるか、あるいは前記ラパマイシン−結合性ドメインの直ぐN −末端側にある配列番号12の1から約500アミノ酸残基までのポリペプチド を表し、そして Z3は、非存在であるか、あるいは前記ラパマイシン−結合性ドメインの直ぐC −末端側にある配列番号2の1から約365アミノ酸残基までのポリペプチドを 表す] により表される、核酸。 37. 一般式A−B−C[式中、 Yは、主に配列番号14のアミノ酸残基Val41−Tyr173、配列番号1 6のVal1−Tyr133、もしくは配列番号18のVal1−Arg133 からなるラパマイシン−結合性ドメイン、あるいはそれらに相同なイーストもし くは真菌類のRAPT1−様蛋白質の対応性ラパマイシン−結合性ドメインを表 し、そして XおよびZは、個別に非存在であるか、あるいはRAPT1−様蛋白質に無関係 なアミノ酸配列を有するポリペプチドを表す] により表されるキメラポリペプチド。 38. 配列番号2もしくは12に少なくとも70%相同なアミノ酸配列を有す る、組換えRAPT1ポリペプチドもしくはその断片。 39. 前記ポリペプチドがFKBP/ラパマイシン複合体に結合する、 請求の範囲28のポリペプチド。 40. i. 配列番号2もしくは12のアミノ酸配列により表されるラ パマイシン−結合性ドメインを含むRAP−BPポリペプチド、および FK506−結合性蛋白質のラパマイシン−結合性ドメイ ンを含むFKBPポリペプチドを、 前記RAP−BPおよびFKBPポリペプチドが相互作用を行うことが可能な 条件下で合わせること; ii. 前記組み合わせ物を検査用化合物と接触させ;そして iii. 前記RAP−BPおよびFKBPポリペプチドを含む複合 体の形成を検出すること、 を含み、 前記検査用化合物の存在下での前記複合体の形成の統計的に有意な増加は、非存 在の場合の前記複合体の形成と比較すると、RAP−結合性蛋白質とFK506 −結合性蛋白質との間の相互作用のインデューサーを示す、 RAP−結合性蛋白質とFK506−結合性蛋白質との結合を誘導する作用物質 について検査用化合物をスクリーニングするためのアッセイ。 41. i. RAPT1もしくはRAPT1−様蛋白質のラパマイシン −結合性ドメインを主に含むRAP−BPポリペプチド、および FK506−結合性蛋白質のラパマイシン−結合性ドメイ ンを含むFKBPポリペプチドを、 前記RAP−BPおよびFKBPポリペプチドが相互作用を行うことが可能な 条件下で合わせること; ii. 前記組み合わせ物を検査用化合物と接触させること;そし て iii. 前記RAP−BPおよびFKBPポリペプチドを含む複合 体の形成を検出すること、 を含み、 前記検査用化合物の存在下での前記複合体の形成の統計的に有意な増加は、非存 在の場合の前記複合体の形成と比較すると、RAP−結合性蛋白質とFK506 −結合性蛋白質との間の相互作用のインデューサーを示す、 RAP−結合性蛋白質とFK506−結合性蛋白質との結合を誘導する作用物質 について検査用化合物をスクリーニングするためのアッセイ。 42. (i) 検出可能な遺伝子を含み、その検出可能な遺伝子は、そ の検出可能な遺伝子が転写活性化ドメインを含み、その転写活性化ドメインがそ の検出可能な遺伝子に十分近接している場合に、あるアミノ酸配列により活性化 される活性化される宿主細胞を提供すること; (ii) その宿主細胞をその宿主細胞内で発現されることが可能 であって、第一ハイブリッド蛋白質をコードするDNA配列を含み、その第一ハ イブリッド蛋白質が: (a) その宿主細胞内の検出可能な遺伝子上の結合部位を認識 するDNA−結合性ドメイン;および (b) FK506−結合性蛋白質のラパマイシン−結合性ドメ イン; を含む第一キメラ遺伝子で形質転換させること; (iii) その宿主細胞をその宿主細胞内で発現されることが可能 であって、第二ハイブリッド蛋白質をコードするDNA配列を含み、その第二ハ イブリッド蛋白質が: (a) 転写活性化ドメイン;および (b) RAPT1−様蛋白質のラパマイシン−結合性ドメイン ; を含むこと; (iv) その宿主細胞を、その第一ハイブリッド蛋白質および第 二ハイブリッド蛋白質がその検出可能な遺伝子が活性化されるのに十分な量で発 現される条件下に供すること; (v) その宿主細胞を検査用作用物質と接触させること;なら びに (vi) その検出可能な遺伝子が、その第一検査用蛋白質と第二 検査用蛋白質との間の総合作用の非存在下での発現と比較すると、統計学的に見 て有意に大きい度合いにまで発現されているかどうかを決定すること、 を含む、 RAP−結合性蛋白質とFK506−結合性蛋白質の結合性を誘導する作用物質 について検査用化合物をスクリーニングするための方法。 43. DNA−結合性ドメインおよび転写活性化ドメインが、分離可能なDN A−結合性ドメインおよび転写活性性ドメインを有する転写活性化因子に由来す る、請求の範囲42の方法。 44. DNA結合性ドメインと転写活性化ドメインとが、転写活性化 因子 GAL4、GCN4、LexA、VP16、およびADR1からなる群よ り選択される、請求の範囲43の方法。 45. FK506−結合性蛋白質のラパマイシン−結合性ドメインが第一ハイ ブリッド蛋白質よりはむしろ第二ハイブリッド蛋白質の部分であり、かつRAP T1−様蛋白質のラパマイシン−結合性ドメインが第二ハイブリッド蛋白質より はむしろ第一ハイブリッド蛋白質の部分である、請求の範囲42の方法。 46. 実質的に精製されたオリゴヌクレオチドを含み、前記オリゴヌクレオチ ドが、緊縮条件下で、配列番号1もしくは11、またはその天然に存在する突然 変異体からなる群より選択される核酸のセンスもしくはアンチセンス配列の内の 少なくとも20の連続ヌクレオチドにハイブリダイズするヌクレオチド配列の領 域を含むプローブ/プライマー。 47. 連結されかつ検出されることが可能なラベル基を更に含む、請求の範囲 46のプローブ/プライマー。 48. 前記ラベルが、放射性同位元素、蛍光化合物、酵素、および酵素補助因 子からなる群より選択される、請求の範囲47のプローブ/プライマー。 49. ある被検体が所望されない細胞増殖を特徴とする障害の危険にさらされ ているかどうかを決定し、かつ前記被検体の組織内で、 配列番号2もしくは12により表される蛋白質、またはそれらの哺乳類相同体 をコードする遺伝子の突然変異;および前記遺伝子の過誤発現、の内の少なくと も一つを特徴とする遺伝子病変の存在もしくは非存在を決定することを含む方法 。 50. 前記病変の検出が、 i. 前記遺伝子からの一つもしくは複数のヌクレオチドの欠失、 ii. 前記遺伝子への一つもしくは複数のヌクレオチドの添加、 iii. 前記遺伝子の一つもしくは複数のヌクレオチドの置換、 iv. 前記遺伝子の総体的染色体再配列、 v. 前記遺伝子のメッセンジャーRNA転写物のレベルの総体的変化、 vi. 前記遺伝子のメッセンジャーRNA転写物の非野生型スプライシン グパターンの存在、 vii. 前記蛋白質の非野生型タイプレベル、 の内の少なくとも一つの存在を確認することを含む、請求の範囲49の方法。 51. 前記遺伝子病変の検出が、 i. 配列番号1もしくは11、またはそれらの天然に存在する突然変異 体、あるいは前記遺伝子に天然の状態で結合する5’もしくは3’フランク配列 からなる群より選択される核酸のセンスもしくはアンチセンス配列にハイブリダ イズするヌクレオチド配列の領域を含むオリゴヌクレオチドを含むプローブ/プ ライマーを提供すること; ii. 前記プローブ/プライマーを前記組織の核酸に露出すること;なら びに iii 前記プローブ/プライマーの前記核酸へのハイブリダイゼーション により前記遺伝子病変の存在もしくは非存在を検出すること、 を含む、請求の範囲49の方法。 52. 前記病変の検出が、前記遺伝子および場合によっては前記フランク核酸 配列のヌクレオチド配列を決定するために前記プローブ/プラ イマーを利用することを含む、請求の範囲51の方法。 53. 前記病変の検出が、ポリメラーゼ連鎖反応(PCR)で前記プローブ/ プライマーを利用することを含む、請求の範囲51の方法。 54. 前記病変の検出が、連結連鎖反応(LCR)で前記プローブ/プライマ ーを利用することを含む、請求の範囲51の方法。 55. 前記蛋白質のレベルが免疫アッセイにおいて検出される、請求の範囲5 1の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25079594A | 1994-05-27 | 1994-05-27 | |
US08/250,795 | 1994-05-27 | ||
US08/360,144 | 1994-12-20 | ||
US08/360,144 US6150137A (en) | 1994-05-27 | 1994-12-20 | Immunosuppressant target proteins |
PCT/US1995/006722 WO1995033052A1 (en) | 1994-05-27 | 1995-05-30 | Immunosuppressant target proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10501135A true JPH10501135A (ja) | 1998-02-03 |
JP4007611B2 JP4007611B2 (ja) | 2007-11-14 |
Family
ID=26941149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50108196A Expired - Lifetime JP4007611B2 (ja) | 1994-05-27 | 1995-05-30 | 免疫抑制剤標的蛋白質 |
Country Status (10)
Country | Link |
---|---|
US (6) | US6150137A (ja) |
EP (2) | EP0760852B1 (ja) |
JP (1) | JP4007611B2 (ja) |
KR (1) | KR100509415B1 (ja) |
AT (1) | ATE282091T1 (ja) |
AU (1) | AU2763095A (ja) |
CA (1) | CA2188061C (ja) |
DE (1) | DE69533748T2 (ja) |
ES (1) | ES2232825T3 (ja) |
WO (1) | WO1995033052A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010525804A (ja) * | 2007-05-01 | 2010-07-29 | ルードウィク インスティテュート オブ キャンサー リサーチ | ラパマイシンの哺乳動物標的(mTOR)タンパク質の切断型変異体 |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112873A (en) | 1994-03-08 | 2005-03-20 | Wyeth Corp | Rapamycin-fkbp12 binding proteins, their isolation and their use |
US6150137A (en) * | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
US20030206891A1 (en) * | 1995-06-07 | 2003-11-06 | Ariad Gene Therapeutics, Inc. | Rapamycin-based biological regulation |
US6506379B1 (en) | 1995-06-07 | 2003-01-14 | Ariad Gene Therapeutics, Inc. | Intramuscular delivery of recombinant AAV |
CA2219080A1 (en) * | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamycin-based regulation of biological events |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
AU714904C (en) * | 1995-06-07 | 2002-08-08 | Ariad Pharmaceuticals, Inc. | Rapamcycin-based regulation of biological events |
WO1997035961A1 (en) * | 1996-03-28 | 1997-10-02 | President And Fellows Of Harvard College | Ubiquitination of the transcription factor e2a |
US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
WO2001014387A1 (en) * | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
EP1108785A1 (en) * | 1999-10-21 | 2001-06-20 | Leadd B.V. | Apoptin-associating protein |
US6828097B1 (en) * | 2000-05-16 | 2004-12-07 | The Childrens Mercy Hospital | Single copy genomic hybridization probes and method of generating same |
US6410340B1 (en) * | 2000-08-23 | 2002-06-25 | Children's Research Institute | Use of an 8.4 kDa protein as an immunophilin reagent in protein binding assays for immunosuppressive drugs |
US20050287510A1 (en) * | 2000-11-10 | 2005-12-29 | Sumrall Kenneth A | Integrated instructional management system and method |
US7037695B2 (en) * | 2001-02-02 | 2006-05-02 | Pharmacia & Upjohn | Methods of assessing wolframin protein activity |
US7273723B2 (en) * | 2001-09-07 | 2007-09-25 | Martin Fussenegger | Antibiotic-based gene regulation system |
EP2407473A3 (en) | 2002-02-01 | 2012-03-21 | ARIAD Pharmaceuticals, Inc | Method for producing phosphorus-containing compounds |
DE10261834A1 (de) * | 2002-12-20 | 2004-07-08 | Phenion Gmbh & Co. Kg | Hochdurchsatz-geeignetes Screening-Verfahren zur Identifikation von Wirkstoffen |
US20060183189A1 (en) * | 2003-09-02 | 2006-08-17 | Martin Fussenegger | Regulatable gene expression in mammalian cells and mammals |
WO2005062708A2 (en) * | 2003-12-29 | 2005-07-14 | Ramot At Tel-Aviv University Ltd. | An assay for the detection of rapamycin and rapamycin analogs |
US20060078875A1 (en) * | 2004-09-23 | 2006-04-13 | The Penn State Research Foundation | Genetic selection of small molecule modulators of protein-protein interactions |
US20080081379A1 (en) * | 2006-07-13 | 2008-04-03 | Sigler Gerald F | Homogeneous double receptor agglutination assay for immunosuppressant drugs |
MX2009008105A (es) * | 2007-01-29 | 2010-03-03 | Wyeth Corp | Ligando de inmunofilina ds y metodos para modular la inmunofilina y la actividad de canal de calcio. |
CA2715080C (en) | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
TWI688395B (zh) | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
JP5922095B2 (ja) | 2010-03-29 | 2016-05-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 薬理学的に誘導される導入遺伝子アブレーション系 |
WO2011133493A2 (en) * | 2010-04-19 | 2011-10-27 | The University Of North Carolina At Chapel Hill | Allosteric regulation of kinase activity |
EP2681327B1 (en) | 2011-03-04 | 2018-11-21 | Intrexon Corporation | Vectors conditionally expressing protein |
US20140031418A1 (en) | 2011-04-20 | 2014-01-30 | The Trustees Of The University Of Pennsylvania | Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens |
US20130210747A1 (en) | 2012-02-13 | 2013-08-15 | University Of Southern California | Methods and Therapeutics Comprising Ligand-Targeted ELPs |
WO2014059385A1 (en) * | 2012-10-12 | 2014-04-17 | University Of Southern California | Methods and small molecule therapeutics comprising fused elps |
WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
EA201792500A1 (ru) | 2015-05-13 | 2018-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Aav-опосредованная экспрессия антител против гриппа и способы их использования |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
CN110139933B (zh) | 2016-11-09 | 2024-03-08 | 英特瑞克斯顿股份有限公司 | 共济蛋白表达构建体 |
JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
SG10201913833PA (en) | 2017-02-28 | 2020-03-30 | Univ Pennsylvania | Influenza vaccines based on aav vectors |
SG10201912976WA (en) | 2017-02-28 | 2020-02-27 | Univ Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
US11464867B2 (en) | 2018-02-13 | 2022-10-11 | University Of Southern California | Multimeric elastin-like polypeptides |
US20240024507A1 (en) | 2020-12-01 | 2024-01-25 | The Trustees Of The University Of Pennsylvania | Novel compositions with tissue-specific targeting motifs and compositions containing same |
BR112023021971A2 (pt) | 2021-04-23 | 2024-02-20 | Univ Pennsylvania | Composições com motivos de direcionamento específicos do cérebro e composições contendo os mesmos |
WO2023056399A1 (en) | 2021-10-02 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Novel aav capsids and compositions containing same |
WO2023147304A1 (en) | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
AU6131086A (en) | 1985-07-05 | 1987-01-30 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4833080A (en) | 1985-12-12 | 1989-05-23 | President And Fellows Of Harvard College | Regulation of eucaryotic gene expression |
CA1319101C (en) | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules |
DE3852304T3 (de) | 1987-03-02 | 1999-07-01 | Enzon Lab Inc | Organismus als Träger für "Single Chain Antibody Domain (SCAD)". |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
WO1989002468A1 (en) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
DE3851153T2 (de) | 1987-12-11 | 1995-01-05 | Whitehead Biomedical Inst | Genetische modifizierung von endothelialen zellen. |
JP2917998B2 (ja) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 修飾された肝細胞およびその用途 |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
WO1992007943A1 (en) | 1990-10-31 | 1992-05-14 | Somatix Therapy Corporation | Retroviral vectors useful for gene therapy |
US5322772A (en) * | 1991-04-09 | 1994-06-21 | Children's Research Institute | Rapamycin assay |
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US5869262A (en) * | 1992-01-27 | 1999-02-09 | Icos Corporation | Method for monitoring an inflammatory disease state by detecting circulating ICAM-R |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
JPH08504091A (ja) | 1992-09-22 | 1996-05-07 | メディカル・リサーチ・カウンシル | 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス |
EP0672131B1 (en) * | 1992-10-30 | 2003-12-17 | The General Hospital Corporation | A novel cell cycle control protein |
US5354845A (en) * | 1993-04-21 | 1994-10-11 | Children's Research Institute | FK-506 and rapamycin specific binding immunophilin |
DE69517010T2 (de) * | 1994-01-04 | 2000-12-21 | Mitotix Inc | Ubiquitin-konjugierende enzyme |
IL112873A (en) * | 1994-03-08 | 2005-03-20 | Wyeth Corp | Rapamycin-fkbp12 binding proteins, their isolation and their use |
US6150137A (en) * | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
-
1994
- 1994-12-20 US US08/360,144 patent/US6150137A/en not_active Expired - Lifetime
-
1995
- 1995-05-30 EP EP95922904A patent/EP0760852B1/en not_active Expired - Lifetime
- 1995-05-30 DE DE69533748T patent/DE69533748T2/de not_active Expired - Lifetime
- 1995-05-30 WO PCT/US1995/006722 patent/WO1995033052A1/en active IP Right Grant
- 1995-05-30 AT AT95922904T patent/ATE282091T1/de not_active IP Right Cessation
- 1995-05-30 EP EP04026560A patent/EP1514931B1/en not_active Expired - Lifetime
- 1995-05-30 JP JP50108196A patent/JP4007611B2/ja not_active Expired - Lifetime
- 1995-05-30 AU AU27630/95A patent/AU2763095A/en not_active Abandoned
- 1995-05-30 ES ES95922904T patent/ES2232825T3/es not_active Expired - Lifetime
- 1995-05-30 KR KR1019960706870A patent/KR100509415B1/ko active IP Right Grant
- 1995-05-30 CA CA2188061A patent/CA2188061C/en not_active Expired - Lifetime
-
1998
- 1998-01-23 US US09/012,515 patent/US6127521A/en not_active Expired - Lifetime
- 1998-01-23 US US09/012,504 patent/US6464974B1/en not_active Expired - Lifetime
- 1998-01-23 US US09/012,399 patent/US6509152B1/en not_active Expired - Fee Related
-
2004
- 2004-06-24 US US10/877,320 patent/US20050059803A1/en not_active Abandoned
-
2009
- 2009-11-25 US US12/625,940 patent/US20110065898A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010525804A (ja) * | 2007-05-01 | 2010-07-29 | ルードウィク インスティテュート オブ キャンサー リサーチ | ラパマイシンの哺乳動物標的(mTOR)タンパク質の切断型変異体 |
Also Published As
Publication number | Publication date |
---|---|
KR100509415B1 (ko) | 2006-04-28 |
AU2763095A (en) | 1995-12-21 |
EP0760852B1 (en) | 2004-11-10 |
US6150137A (en) | 2000-11-21 |
DE69533748T2 (de) | 2005-11-03 |
US6464974B1 (en) | 2002-10-15 |
JP4007611B2 (ja) | 2007-11-14 |
US20050059803A1 (en) | 2005-03-17 |
EP1514931A1 (en) | 2005-03-16 |
CA2188061A1 (en) | 1995-12-07 |
WO1995033052A1 (en) | 1995-12-07 |
CA2188061C (en) | 2012-09-25 |
ES2232825T3 (es) | 2005-06-01 |
DE69533748D1 (de) | 2004-12-16 |
US20110065898A1 (en) | 2011-03-17 |
US6509152B1 (en) | 2003-01-21 |
KR970703422A (ko) | 1997-07-03 |
US6127521A (en) | 2000-10-03 |
ATE282091T1 (de) | 2004-11-15 |
EP0760852A1 (en) | 1997-03-12 |
EP1514931B1 (en) | 2010-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10501135A (ja) | 免疫抑制剤標的蛋白質 | |
US6150099A (en) | NF-AT polypeptides and polynucleotides | |
WO1995033052A9 (en) | Immunosuppressant target proteins | |
KR100404011B1 (ko) | 세포-주기조절단백질및그것의사용방법 | |
US6486131B2 (en) | Cell-cycle regulatory proteins, and uses related thereto | |
US6352830B1 (en) | NF-AT polypeptides and polynucleotides and screening methods for immunosuppressive agents | |
WO1995033819A2 (en) | Cdk4 (cyclin dependent kinase 4) binding proteins | |
US5756671A (en) | CDC37 cell-cycle regulatory protein, and uses related thereto | |
JP2002510490A (ja) | Lystタンパク質複合体およびlyst相互作用タンパク質 | |
US6747128B2 (en) | Components of ubiquitin ligase complexes, and uses related thereto | |
US7691632B2 (en) | Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression | |
WO2000053733A2 (en) | Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof | |
US6127158A (en) | Ubiquitin conjugating enzymes | |
US20030064408A1 (en) | Protein-protein interactions | |
AU777192B2 (en) | Immunosuppressant target proteins | |
AU735874B2 (en) | Immunosuppressant target proteins | |
WO1996040767A2 (en) | E6ap-binding proteins | |
US20030100489A1 (en) | Cell-cycle regulatory proteins, and uses related thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060525 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061004 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070717 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070828 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100907 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110907 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120907 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130907 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |